(Q33420238)

English

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

26 July 2017

0 references

multicenter clinical trial

0 references

thrombocytopenia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Waleed Ghanima

1

0 references

Geir Erland Tjønnfjord

5

object named as

Geir E Tjønnfjord

1 reference

Europe PubMed Central

26 July 2017

author name string

Abderrahim Khelif

2

1 reference

Europe PubMed Central

26 July 2017

Anders Waage

3

1 reference

Europe PubMed Central

26 July 2017

Marc Michel

4

1 reference

Europe PubMed Central

26 July 2017

Neila Ben Romdhan

6

1 reference

Europe PubMed Central

26 July 2017

Johannes Kahrs

7

1 reference

Europe PubMed Central

26 July 2017

Bernadette Darne

8

1 reference

Europe PubMed Central

26 July 2017

Pål Andrè Holme

9

1 reference

Europe PubMed Central

26 July 2017

RITP study group

10

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

5 February 2015

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

385

1 reference

Europe PubMed Central

26 July 2017

9978

1 reference

Europe PubMed Central

26 July 2017

1653-1661

1 reference

Europe PubMed Central

26 July 2017

The ITP syndrome: pathogenic and clinical diversity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

International consensus report on the investigation and management of primary immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Morbidity and mortality in adults with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Is splenectomy still the gold standard for the treatment of chronic ITP?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961495-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61495-1

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33420238&oldid=1968828944"